High-intensity focused ultrasound therapy for prostate cancer

International Journal of Urology

Volumn 19, Issue 3, 2012, Pages 187-201

  Uchida, Toyoaki ^a   Nakano, Mayura ^a   Hongo, Satoko ^a   Shoji, Sunao ^a   Nagata, Yohishiro ^a   Satoh, Takefumi ^b   Baba, Shiro ^b   Usui, Yukio ^c   Terachi, Toshiro ^c  

^a TOKAI UNIVERSITY HACHIOJI HOSPITAL   (Japan)

^b KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

High intensity focused ultrasound; Prostatic cancer; Safety; Survival; Systematic review; Thermal ablation

Indexed keywords

CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; DISEASE FREE SURVIVAL; EPIDIDYMITIS; ERECTILE DYSFUNCTION; FOLLOW UP; HIGH INTENSITY FOCUSED ULTRASOUND; HUMAN; PATIENT SAFETY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CARCINOMA; PROSTATECTOMY; RECURRENT CANCER; REVIEW; TREATMENT OUTCOME; URETHRA STRICTURE; URINARY TRACT INFECTION; URINE INCONTINENCE; URINE RETENTION;

HUMANS; HYPERTHERMIA, INDUCED; MALE; PROSTATIC NEOPLASMS; ULTRASONIC THERAPY;

EID: 84857363303     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2011.02936.x     Document Type: Review

References (86)

1. Jemel A, Siegel R, Ward E etal. Cancer statistics 2008. CA Cancer J. Clin. 2008; 58: 71-96.
2. Ferlay J, Autier P, Boniol M etal. Estimates of cancer incidence and mortality in Europe in 2006. Ann. Oncol. 2007; 18: 581-92.
3. Cancer Statistics Update 2009. Tokyo Foundation. [Cited 24 September 2011.] Available fromURL: (figures6 and 15).
4. Bill-Axelson A, Holmberg L, Filén F etal. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J. Natl. Cancer Inst. 2008; 100: 1144-54.
5. Boorjian SA, Thompson RH, Tollefson MK etal. Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence. Eur. Urol. 2011; 59: 893-9.
6. Zelefsky MJ, Kuban DA, Levy LB etal. Multi-institutional analysis of long-term outcome for stage T1-T2 prostate cancer treated with permanent seed implantation. Int. J. Radiat. Oncol. Biol. Phys. 2007; 67: 327-33.
7. Kupelian PA, Willoughby TR, Reddy CA etal. Hypofractionated intensity-modulated radiotherapy (70Gy at 2.5Gy per fraction) for localized prostate cancer: Cleveland Clinic experience. Int. J. Radiat. Oncol. Biol. Phys. 2007; 68: 1424-30.
8. Tooher R, Swindle P, Woo H etal. Laparoscopic radical prostatectomy for localized prostate cancer: a systematic review of comparative studies. J. Urol. 2006; 175: 2011-17.
9. Cohen JK, Miller RJ Jr, Ahmed S etal. Ten-year biochemical disease control for patients with prostate cancer treated with cryosurgery as primary therapy. Oncology 2008; 71: 515-18.
10. Kawakami J, Cowan JE, Elkin EP etal. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). Cancer 2006; 106: 1708-14.
11. Lynn JG, Putnam TJ. Histology of Cerebral Lesions Produced by Focused Ultrasound. Am. J. Pathol. 1944; 20: 637-49.
12. Fry WJ, Barnard JW, Fry EJ, Krumins RF, Brennan JF. Ultrasonic lesions in the mammalian central nervous system. Science 1955; 122: 517-18.
13. Madersbacher S, Pedevilla M, Vingers L, Susani M, Marberger M. Effect of high-intensity focused ultrasound on human prostate cancer in vivo. Cancer Res. 1995; 55: 3346-51.
14. Beerlage HP, van Leenders GJ, Oosterhof GO etal. High-intensity focused ultrasound (HIFU) followed after one to two weeks by radical retropubic prostatectomy: results of a prospective study. Prostate 1999; 39: 41-6.
15. Zhou Y-U. High intensity focused ultrasound in clinical tumor ablation. World J. Clin. Oncol. 2011; 10: 8-27.
16. Rewcastle JC. High intensity focused ultrasound for prostate cancer: a review of the scientific foundation, technology and clinical outcomes [review]. Technol. Cancer Res. Treat. 2006; 5: 619-25.
17. Poissonnier L, Chapelon J-Y, Rouvière O etal. Control of prostate cancer by transrectal HIFU in 227 patients. Eur. Urol. 2007; 51: 381-7.
18. Illing R, Emberton M. Sonablate-500: Transrectal high-intensity focused ultrasound for the treatment of prostate cancer [review]. Expert Rev. Med. Devices 2006; 3: 717-29.
19. Gelet A, Chapelon JY, Bouvier R etal. Treatment of prostate cancer with transrectal focused ultrasound: early clinical experience. Eur. Urol. 1996; 29: 174-83.
20. Crouzet S, Rebillard X, Chevallier D etal. Multicentric Oncologic outcomes of high-intensity focused ultrasound for localized prostate cancer in 803 patients. Eur. Urol. 2010; 58: 559-66.
21. Chaussy C, Thüroff S. The status of high-intensity focused in the treatment of localized prostate cancer and the impact of a combined resection. Curr. Urol. Rep. 2003; 4: 248-52.
22. Blana A, Rogenhofer S, Ganzer R etal. Eight years' experience with high-intensity focused ultrasonography for treatment of localized prostate cancer. Urology 2008; 72: 1329-33.
23. Vallancien G, Prapotnich D, Cathelineau X, Baumert H, Rozet F. Transrectal focused ultrasound combined with transurethral resection of the prostate for the treatment of localized prostate cancer: feasibility study. J. Urol. 2004; 171: 2265-7.
24. Misraï V, Rouprêt M, Chartier-Kastler E etal. Oncologic control provided by HIFU therapy as single treatment in men with clinically localized prostate cancer. World J. Urol. 2008; 26: 481-5.
25. Lee H, Hong J, Choi H. High-intensity focused ultrasound therapy for clinically localized prostate cancer. Prostate Cancer Prostatic Dis. 2006; 9: 439-43.
26. Ripert T, Azémar M-D, Ménard J etal. Six years' experience with high-intensity focused ultrasonography for prostate cancer: oncological outcomes using the new "Stuttgart" definition for biochemical failure. BJU Int. 2010; 107: 1899-905.
27. Uchida T, Sanghvi NT, Gardner TA etal. Transrectal high-intensity focused ultrasound for treatment of patients with stage T1b-2N0M0 localized prostate cancer: a preliminary report. Urology 2002; 59: 394-8.
28. Uchida T, Shoji S, Nakano M etal. Transrectal high-intensity focused ultrasound for the treatment of localized prostate cancer: eight-year experience. Int. J. Urol. 2009; 16: 881-6.
29. Sumitomo M, Asakuma J, Sato A, Ito K, Nagakura K, Asano T. Transurethral resection of the prostate immediately after high-intensity focused ultrasound treatment for prostate cancer. Int. J. Urol. 2010; 17: 924-39.
30. Inoue Y, Goto K, Hayashi T, Hayashi M. Transrectal high-intensity focused ultrasound for treatment of localized prostate cancer. Int. J. Urol. 2011; 18: 358-63.
31. Mearini L, D'Urso L, Collura D etal. Visually directed transrectal high intensity focused ultrasound for the treatment of prostate cancer: a preliminary report on the Italian experience. J. Urol. 2009; 181: 105-12.
32. Fujise Y, Azuma H, Inamoto T etal. Neoadjuvant hormonal therapy dose not impact the treatment success of high-intensity focused ultrasound for the treatment of localized prostate cancer. World J. Urol. 2011; 29: 689-94.
33. Ahmed HU, Zacharakis E, Dudderidge T etal. High-intensity focused ultrasound in the treatment of primary prostate cancer: the first UK series. Br. J. Cancer 2009; 101: 19-26.
34. Gelet A, Chapelon JY, Poissonnier L etal. Local recurrence of prostate cancer after external beam radiotherapy: early experience of salvage therapy using high-intensity focused ultrasonography. Urology 2004; 63: 625-9.
35. Murat FJ, Poissonnier L, Rabilloud M etal. Mid-term results demonstrate salvage high-intensity focused ultrasound (HIFU) as an effective acceptably morbid salvage treatment option for locally radiorecurrent prostate cancer. Eur. Urol. 2009; 55: 640-7.
36. Zacharakis E, Ahmed H-U, Ishaq A etal. The feasibility and safety of high-intensity focused ultrasound as salvage therapy for recurrent prostate cancer following external beam radiotherapy. BJU Int. 2008; 102: 786-92.
37. Uchida T, Shoji S, Nakano M etal. High-intensity focused ultrasound as salvage therapy for patients with recurrent prostate cancer after external beam radiation, brachytherapy or proton therapy. BJU Int. 2010; 107: 378-82.
38. Ahmed HU, Ishaq A, Zacharakis E etal. Rectal fistula after salvage high-intensity focused ultrasound for recurrent prostate cancer after combined brachytherapy and external beam radiotherapy. BJU Int. 2009; 102: 321-23.
39. Muto S, Yoshii T, Saito K etal. Focal therapy with high-intensity focused ultrasound in the treatment of localized prostate cancer. Jpn. J. Clin. Oncol. 2008; 38: 192-9.
40. Ahmed HU, Freeman A, Kirkham A etal. Focal therapy for localized prostate cancer: a phase I/II trial. J. Urol. 2011; 185: 1246-55.
41. El Fegoun AB, Barret E, Prapotnich D etal. Focal therapy with high-intensity focused ultrasound for prostate cancer in the elderly. A feasibility study with 10years follow-up. Int. Braz. J. Urol. 2011; 37: 213-22.
42. Uchida T, Kim H, Nakano M etal. Focal therapy for localized prostate cancer. Jpn. J. Endourol. 2011; 24: 194-9.
43. Hayashi M, Shinmei S, Asano K. Transrectal high-intensity focused ultrasound for treatment for patients with biochemical failure after radical prostatectomy. Int. J. Urol. 2007; 14: 1048-50.
44. Murota-Kawano A, Nakano M, Hongo S etal. Salvage high-intensity focused ultrasound for biopsy-confirmed local recurrence of prostate cancer after radical prostatectomy. BJU Int. 2010; 105: 1642-5.
45. American Society for Therapeutic and Oncology Consensus Panel. Consensus statement: guidelines for PSA following radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 1977; 37: 1035-41.
46. Roach M III, Hanks G, Thames H Jr etal. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer. Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int. J. Radiat. Oncol. Biol. Phys. 2006; 65: 965-74.
47. Blana A, Brown SC, Chaussy C etal. High-intensity focused ultrasound for prostate cancer: comparative definitions of biochemical failure. BJU Int. 2009; 104: 1058-62.
48. Foster RS, Bihrle R, Sanghvi NT etal. High-intensity focused ultrasound in the treatment of prostate disease. Eur. Urol. 1993; 23 (Suppl 1): 29-33.
49. Gelet A, Chaperon JY, Margonari J etal. High - intensity focused ultrasound experimentation on human benign prostatic hypertrophy. Eur. Urol. 1993; 23 (Suppl 1): 44-7.
50. Bihrle R, Foster RS, Sanghvi NT etal. High intensity focused ultrasound for the treatment of benign prostatic hyperplasia: early United States clinical experience. J. Urol. 1994; 151: 1271-5.
51. Sullivan LD, McLoughlin MG, Goldenberg LG etal. Early experience with high-intensity focused ultrasound for the treatment of benign prostatic hypertrophy. Br. J. Urol. 1997; 79: 172-6.
52. Uchida T, Muramoto M, Kyunou H etal. Clinical outcome of high-intensity focused ultrasound for treating benign prostatic hyperplasia: preliminary report. Urology 1998; 42: 66-71.
53. Madersbacher S, Schatzl G, Djavan B etal. Long-term outcome of transrectal high-intensity focused ultrasound therapy for benign prostatic hyperplasia. Eur. Urol. 2000; 37: 687-94.
54. Ter Haar G, Coussios C. High intensity focused ultrasound: physical principles and device. Int. J. Hyperthermia 2007; 23: 89-104.
55. Chapelon JY, Margonari J, Vernier F etal. In vivo effects of high-intensity focused ultrasound on prostate adenocarcinoma Dunning R3327. Cancer Res. 1992; 52: 6353-7.
56. Gelet A, Chapelon JY, Margonari J etal. Prostatic tissue destruction by high-intensity focused ultrasound: experimentation on canine prostate. J. Endourol. 1993; 7: 249-53.
57. Minei S, Chen W, Uchida T. Effect of high-intensity focused ultrasound on PC3 prostate cancer: in vitro and vivo analysis. Kitasato Med. 2001; 31: 319-26.
58. Chen W-H, Carlson R, Weis CC, Seip R, Sanghvi NT. System and method for tissue change monitoring during HIFU treatment. United States Patent Application. Pub. No.: 2009/0069677 A1, Pub. Date: Mar 12, 2009.
59. Uchida T, Illing RO, Cathcart PJ, Emberton M. To what extent does the prostate-specific antigen nadir predict subsequent treatment failure after transrectal high-intensity focused ultrasound therapy for presumed localized adenocarcinoma of the prostate? BJU Int. 2006; 98: 537-9.
60. Ganzer R, Rogenhofer S, Walter B etal. PSA nadir is a significant predictor of treatment failure after high-intensity focused ultrasound (HIFU) treatment of localized prostate cancer. Eur. Urol. 2008; 53: 547-53.
61. Shoji S, Nakano S, Nagata Y etal. Quality of life following high-intensity-focused ultrasound for the treatment of localized prostate cancer: a prospective study. Int. J. Urol. 2010; 17: 715-19.
62. Blana A, Rogenhofer S, Ganzer R, Wild P, Wieland W, Walter B. Morbidity associated with repeated transrectal high-intensity focused ultrasound of localized prostate cancer. World J. Urol. 2006; 24: 535-90.
63. Bostwick DG, Waters DJ, Farley ER etal. Group consensus reports from the Consensus Conference on Focal Treatment of Prostatic Carcinoma, Celebration, Florida, February 24, 2006. Urology 2007; 70 (6 Suppl): 42-4.
64. Eggener SE, Scardino PT, Carroll PR etal. Focal therapy for localized prostate cancer: a critical appraisal of rationale and Modalities. J. Urol. 2006; 178: 2260-67.
65. Lecornet E, Ahmed HU, Moore CM, Emberton M. Conceptual Basis for focal therapy in prostate cancer. J. Endourol. 2010; 24: 811-18.
66. Ellis DS, Manny TB Jr, Rewcastle JC. Focal cryotherapy followed by penile rehabilitation as primary treatment for localized prostate cancer: initial results. Urology 2007; 70: 9-15.
67. Lindner U, Weersink RA, Haider MA etal. Image guided photothermal focal therapy for localized prostate cancer: phase I trial. J. Urol. 2009; 182: 1371-77.
68. Ahmed HU, Moore C, Emberton M. Minimally-invasive technologies in urooncology: the role of cryotherapy, HIFU and photodynamic therapy in whole gland and focal therapy of localized prostate cancer. Surg. Oncol. 2009; 18: 219-32.
69. Shipley WU, Thames HD, Sandler HM etal. Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis. JAMA 1999; 281: 598-604.
70. Kuban DA, Thames HD, Levy LB etal. Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era. Int. J. Radiat. Oncol. Biol. Phys. 2003; 57: 915-28.
71. Zelefsky MJ, Kuban DA, Levy LB etal. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. Int. J. Radiat. Oncol. Biol. Phys. 2007; 67: 327-33.
72. Coen JJ, Zietman AL, Thakral H, Shipley W. Radical radiation for localized prostate cancer: local persistence of disease results in a late wave of metastasis. J. Clin. Oncol. 2002; 20: 3199-205.
73. Nguyen PL, D'Amico AV, Lee AK, Suh WW. Patient selection, cancer control, and complications after salvage local therapy for post radiation prostate specific antigen failure: a systematic review of the literature. Cancer 2007; 110: 1417-28.
74. Kimura M, Mouraviev V, Tsivian M etal. Current salvage methods for recurrent prostate cancer after failure of primary radiotherapy. BJU Int. 2010; 105: 191-201.
75. Paparel P, Cronin AM, Savage C, Scardino PT, Eastham JA. Oncologic outcome and patterns of recurrence after salvage radical prostatectomy. Eur. Urol. 2009; 55: 404-10.
76. Pisters LL, Leibovici D, Blute M etal. Locally recurrent prostate cancer after initial radiation therapy: a comparison of salvage radical prostatectomy versus cryotherapy. J. Urol. 2009; 182: 517-27.
77. Tharp M, Hardacre M, Bennett R etal. Prostate high-dose-rate brachytherapy as salvage treatment of local failure after previous external or permanent seed irradiation for prostate cancer. Brachytherapy 2008; 7: 231-6.
78. Eandi JA, Link BA, Nelson RA etal. Robotic assisted laparoscopic salvage prostatectomy for radiation resistant prostate cancer. J. Urol. 2010; 183: 133-7.
79. Berge V, Baco E, Dahl AA, Karlsen SJ. Health-related quality of life after salvage high-intensity focused ultrasound (HIFU) treatment for locally radiorecurrent prostate cancer. Int. J. Urol. 2011; 18: 646-51.
80. Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J. Urol. 2003; 169: 517-23.
81. Chun FK, Graefen M, Zacharias M etal. Anatomic radical retropubic prostatectomy-long-term recurrence-free survival rates for localized prostate cancer. World J. Urol. 2006; 24: 273-80.
82. Heidenreich A, Aus G, Bolla M etal. EAU guidelines on prostate cancer. Eur. Urol. 2008; 53: 68-80.
83. Stephenson AJ, Shariat SF, Zelefsky MJ etal. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA 2004; 291: 1325-32.
84. Stephenson AJ, Scardino PT, Kattan MW etal. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J. Clin. Oncol. 2007; 25: 2035-41.
85. Chalasani V, Iansavichene AE, Lock M etal. Salvage radiotherapy following radical prostatectomy. Int. J. Urol. 2009; 16: 31-6.
86. Mottet N, Bellmunt J, Bolla M etal. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur. Urol. 2011; 59: 572-83.